Status:
COMPLETED
A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.
Lead Sponsor:
mAbxience Research S.L.
Conditions:
Healthy Volunteers
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, safety and immunogenicity profile of MB02-DM with MB02-SP and US-Avastin® in healthy male subjects...
Detailed Description
The primary PK parameter endpoints are Cmax and AUC0-∞ for bevacizumab. The secondary PK endpoints will include all other PK parameters for bevacizumab, including tmax, t1/2, CL and AUC(0-t). The ser...
Eligibility Criteria
Inclusion
- Males of any race, between 18 and 55 years of age, inclusive, at Screening.
- Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening.
- Total body weight between 50 and 95 kg, inclusive, at Screening.
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital non-haemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
- Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within normal range at Screening and Check in as follows. A single repeat test will be allowed at each timepoint.
- Absolute neutrophil count ≥1.5 × 109 L
- Platelet count ≥100 × 109 L
- Haemoglobin \>10 g/dl
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x ULN
- Alkaline phosphatase (ALP) ≤1.5 × ULN
- Total bilirubin \<1.5 × ULN (\<51.30 µmol/L in subjects with Gilbert's syndrome)
- Blood urea nitrogen ≤1.5 × ULN
- Creatinine \<132.63 µmol/L
- Serum albumin: \>35 g/L
- Low density lipoprotein cholesterol ≤ 4.9 mmol/L
- High density lipoprotein cholesterol ≥ 0.85 mmol/L
- Creatine kinase (CK) \<2 × ULN
- International normalised ratio (INR) 0.8 to 1.3
- Urine dipstick for proteinuria \<2+
- Systolic blood pressure ≥90 mmHg and \<140 mmHg and diastolic blood pressure ≥50 mmHg and \<90 mmHg at Screening and Check in.
- Subjects agree to use contraception.
- Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.
Exclusion
- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
- Any current or recent history of active infections, including localised infections (Within 2 months prior Screening Visit for any serious infection which requires hospitalization or intravenous anti-infective, and within 14 days prior Screening Visit for any active infection which requires oral treatment).
- History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit.
- Presence of a nonhealing wound or fracture.
- Known history of clinically significant essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions.
- Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study.
- Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive alcohol breath test and/or urinary drug test screen (confirmed by repeat) at Screening or Check in.
- History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency.
- History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis.
- History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae.
- Alcohol consumption of \>24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
- Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator.
- Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study.
- Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
- Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee.
- Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
- Have received a live or attenuated vaccine from 3 months prior to Screening or have the intention to receive a vaccine during the study.
- Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing.
- Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor.
- Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or positive cotinine test upon Screening or Check-in.
- Receipt of blood products within 60 days prior to Check-in.
- Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or platelets from 42 days prior to Screening.
- Poor peripheral venous access.
- History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs.
- Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab.
- Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
- Vulnerable subjects (e.g. persons kept in detention).
- Subjects who are study site employees or immediate family members of a study site or Mabxience employee.
Key Trial Info
Start Date :
January 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 2 2021
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04408989
Start Date
January 11 2021
End Date
September 2 2021
Last Update
September 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland Clinical Studies
Auckland, New Zealand, 1010
2
Christchurch Clinical Studies Trust
Christchurch, New Zealand, 8011